Side-effects and treatment with clozapine: A comparison between the views of consumers and their clinicians

International Journal of Mental Health Nursing

Volumn 17, Issue 1, 2008, Pages 2-8

  Hodge, Kay ^a   Jespersen, Sean ^a  

^a Werribee Mercy Mental Health Program   (Australia)

Author keywords

Adverse effects; Clozapine; Quality of life

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; COMPARATIVE STUDY; DRUG MONITORING; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; MIDDLE AGED; NURSING; PREVALENCE; PSYCHOSIS; QUALITY OF LIFE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; CLOZAPINE; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; VICTORIA;

EID: 38348999007     PISSN: 14458330     EISSN: 14470349     Source Type: Journal    
DOI: 10.1111/j.1447-0349.2007.00506.x     Document Type: Article

References (14)

1. Angermeyer, M. C., Loffler, W., Muller, P. et al. (2001). Patients' and relatives' assessments of clozapine treatment. Psychological Medicine, 31 (3 509 517.
2. Atkinson, M., Zibin, S. Chuang, H. (1997). Characterising quality of life among patients with chronic mental illness: A critical examination of the self-report methodology. American Journal of Psychiatry, 154 (1 99 105.
3. Corrigan, P. W. Buican, B. (1995). The construct validity of subjective quality of life for the severely mentally ill. Journal of Nervous and Mental Diseases, 183 (5 281 285.
4. Day, J. C., Kinderman, P. Bentall, R. P. (1998). A comparison of patients' and prescribers' beliefs about neuroleptic side effects: Prevalence, distress and causation. Acta Psychiatrica Scandinavica, 97, 93 97.
5. Day, J. C., Wood, G., Dewey, M. Bentall, R. P. (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. British Journal of Psychiatry, 166, 650 653.
6. Lehman, F. (1983). The well-being of chronic mental patients: Assessing their quality of life. Archives of General Psychiatry, 40 (4 369 373.
7. Meltzer, H. Y. (1992). Dimensions of outcomes with clozapine. British Journal of Psychiatry, 160 (Suppl. 17 S46 S53.
8. Meltzer, H. Y. (1995). Multiple outcome criteria in schizophrenia: An overview of outcome with clozapine. European Psychiatry, 10 (Suppl. 1 S19 S25.
9. Naber, D. (1995). A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. International Clinical Psychopharmacology, 10 (Suppl. 3 S133 S138.
10. Naber, D. (1998). Subjective experiences of schizophrenia patients treated with antipsychotic medication. International Clinical Psychopharmacology, 13 (Suppl. 1 S14 S45.
11. Therapeutic Guidelines (2003). Therapeutic Guidelines: Psychotropic, Version 5. Melbourne : Therapeutic Guidelines.
12. Voruganti, L., Heslegrave, R., Awad, A. G. Seeman, M. V. (1998). Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability. Psychological Medicine, 28, 165 172.
13. Waserman, J. Criollo, M. (2000). Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatric Services, 51 (5 666 668.
14. Wolfson, P. M. Paton, C. (1996). Clozapine audit: What do patients and relatives think? Journal of Mental Health, 5 (3 267 273.